Global Orphan Diseases Partnering 2010-2017: Deal Trends, Players and Financials - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials" report to their offering.

Global Orphan Diseases Partnering 2010 to 2017 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Orphan Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Orphan Diseases partnering agreement structure

Orphan Diseases partnering contract documents

Top Orphan Diseases deals by value

Most active Orphan Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.

The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in Orphan Diseases dealmaking

2.1. Introduction

2.2. Orphan Diseases partnering over the years

2.3. Orphan Diseases partnering by deal type

2.4. Orphan Diseases partnering by industry sector

2.5. Orphan Diseases partnering by stage of development

2.6. Orphan Diseases partnering by technology type

2.7. Orphan Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Orphan Diseases partnering

3.1. Introduction

3.2. Disclosed financials terms for Orphan Diseases partnering

3.3. Orphan Diseases partnering headline values

3.4. Orphan Diseases deal upfront payments

3.5. Orphan Diseases deal milestone payments

3.6. Orphan Diseases royalty rates

4. Leading Orphan Diseases deals and dealmakers

4.1. Introduction

4.2. Most active in Orphan Diseases partnering

4.3. List of most active dealmakers in Orphan Diseases

4.4. Top Orphan Diseases deals by value

5. Orphan Diseases contract document directory

5.1. Introduction

5.2. Orphan Diseases partnering deals where contract document available

6. Orphan Diseases dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Orphan Diseases therapeutic target

Appendices

Appendix 1 - Directory of Orphan Diseases deals by company A-Z 2010 to 2017

Appendix 2 - Directory of Orphan Diseases deals by deal type 2010 to 2017

Appendix 3 - Directory of Orphan Diseases deals by stage of development 2010 to 2017

Appendix 4 - Directory of Orphan Diseases deals by technology type 2010 to 2017

Further reading on dealmaking

Deal type definitions

About

For more information about this report visit http://www.researchandmarkets.com/research/jx3f2x/global_orphan

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals